886372-76-5

Basic information

• Product Name: 5-BROMO-2-ETHOXY-3-NITRO-PYRIDINE
• Synonyms: 5-BROMO-2-ETHOXY-3-NITRO-PYRIDINE
• CAS NO: 886372-76-5
• Molecular Formula: C₇H₇BrN₂O₃
• Molecular Weight: 247.04608
• Mol File: 886372-76-5.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-BROMO-2-ETHOXY-3-NITRO-PYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-BROMO-2-ETHOXY-3-NITRO-PYRIDINE(886372-76-5)
• EPA Substance Registry System: 5-BROMO-2-ETHOXY-3-NITRO-PYRIDINE(886372-76-5)

Safety Data

• Hazardous Substances Data: 886372-76-5(Hazardous Substances Data)

Upstream product

• 67443-38-3 5-bromo-2-chloro-3-nitropyridine 
• 141-52-6 sodium ethanolate 
• 64-17-5 ethanol 

Downstream Products

• 886373-00-8 5-bromo-2-ethoxypyridin-3-amine 
• 848243-20-9 5-bromo-2-ethoxy-3-iodopyridine 
• 1086063-48-0 N-[5-bromo-2-(ethyloxy)-3-pyridinyl]benzenesulfonamide 

Relevant articles and documents

TYK2 INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.

Discovery of 3-Quinazolin-4(3 H)-on-3-yl-2, N-dimethylpropanamides as Orally Active and Selective PI3Kα Inhibitors

Phosphoinositide 3-kinases (PI3Ks) mediate a series of events related to cell growth, proliferation, survival, and differentiation. Overexpression of PI3Ks can lead to the dysregulation of cell homeostasis and cause tumorigenesis. In this study, rationally designed compounds were investigated as PI3Kα-selective inhibitors. Our efforts culminated in the discovery of a series of quinazolin-4(3H)-one derivatives with 2-substituted-N-methylpropanamide substitutions as PI3Kα-selective inhibitors. The best compound, 10, has PI3Kα enzymatic and cellular IC50 values of 1.8 and 12.1 nM, respectively. It exhibits biochemical selectivities for PI3Kα over PI3Kβ/δ/γof 150/7.72/7.67-fold and cellular selectivities of 115/15.1/>826-fold, respectively. Compound 10 is 59% orally bioavailable with a dose-normalized AUC of 3090 nM. These effects translated into in vivo conditions, as 10 significantly time- and dose-dependently inhibited phosphorylation of Akt in BT-474 subcutaneous xenograft mice and inhibited tumor growth.

COMPOUNDS AND COMPOSITIONS AS RAF KINASE INHIBITORS

The present invention provides compounds of Formula (I) and (II) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.

BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES

The invention is directed to compounds of formula (I), and pharmaceutically acceptable salts or solvates thereof, as well as methods of making and using the compounds.

4-CARBOXAMIDE INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF P13-KINASES

The invention is directed to certain novel compounds. Specifically, the invention is directed to compounds of formula (I) and salts thereof. The compounds of the invention are inhibitors of P13-kinase activity.